Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Alessandrini A, Starace M, Bruni F, Brandi N, Baraldi C, Misciali C, Fanti PA, Piraccini BM (2019) Alopecia areata incognita and diffuse alopecia areata: clinical, trichoscopic, histopathological, and therapeutic features of a 5-year study
GLP-1 receptor agonists can be valuable tools for managing diabetes and weight in patients with Hashimoto's disease when used appropriately and with proper monitoring
Visceral fat, often deemed dangerous fat, is associated with various health risks, underscoring the importance of its reduction for overall well-being
Invega Sustenna/Xeplion/Invega Trinza/Trevicta (paliperidone) Disease area(s): Psychiatry Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $4.22 billion Why it sold so well: In 2024, J&Js long-acting antipsychotic portfolio including Invega Sustenna, Xeplion, Invega Trinza and Trevicta registered global sales of $4.22 billion, reflecting a 2.6% year-over-year increase
